Cardiovascular Disease

Research from D. Pereg et al broadens understanding of cardiovascular disease

Published in Hematology Week, November 17th, 2008

"Recently, bevacizumab, the novel humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF), has shown promising preclinical and clinical anti-cancer activity," scientists in Kefar Sava, Israel report.

"However, concerns have been raised regarding a possible increased risk for arterial thrombo-embolic events associated with its administration, especially in patients with pre-existing cardiovascular disease. On the other hand, bevacizumab treatment is associated with an increased bleeding risk that may be augmented by the co-administration of anti-platelet drugs such as aspirin and clopidogrel," wrote D. Pereg and colleagues.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hematology Week

Source: Hematology Week (2008-11-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry